Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PLUTO: A Prospective Phase II Study of Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy

NCT06114940 is registered in ClinicalTrials.gov with Jinling Hospital, China as lead sponsor.

NCT NCT06114940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06114940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PLUTO: A Prospective Phase II Study of Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy
Lead sponsor
Jinling Hospital, China
Phase
Phase 2
Overall status
Terminated
Start date
December 20, 2022
Completion date
January 10, 2026
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma (rcc)